Cialis vs Viagra: Long-Term Durability of Response

What "Durability of Response" Actually Means in ED Pharmacology

Durability of response refers to whether a drug continues to produce reliable erections after months or years of repeated use, not just on the first dose. Two components matter: pharmacodynamic durability (the drug still works at the receptor level) and pharmacokinetic durability (the drug is still present in sufficient concentration when sex is attempted).

Both tadalafil and sildenafil act by inhibiting phosphodiesterase type 5, raising cyclic guanosine monophosphate in corpus cavernosum smooth muscle and amplifying nitric-oxide-mediated vasodilation. Goldstein et al. (NEJM, 1998) published the landmark phase-3 sildenafil trial demonstrating that 69% of all attempts at sexual intercourse were successful on sildenafil 50 to 100 mg versus 22% on placebo (N=532), establishing the benchmark against which later PDE5 inhibitors are judged.

Why Half-Life Shapes Long-Term Satisfaction

A drug's half-life determines how many doses a man takes per month and, critically, how often he faces the "timing problem" that leads to missed doses or abandoned attempts. Sildenafil's half-life of 3 to 5 hours means a man must dose 30 to 60 minutes before anticipated intercourse. Miss that window and the opportunity is gone. Tadalafil's half-life of 17.5 hours allows dosing up to 24 hours before and still provides activity at 36 hours post-dose, a practical difference that compounds over a year of use. FDA prescribing information for tadalafil documents this extended window formally.

Tachyphylaxis Risk Over Time

Neither agent shows true pharmacodynamic tachyphylaxis (receptor downregulation) in published two-year data. Response rates measured by the International Index of Erectile Function (IIEF) erectile function domain remain stable from month 3 to month 24 in open-label extension data, suggesting the PDE5 enzyme does not upregulate meaningfully in response to chronic inhibition at standard doses.

The Brock 2002 Trial: The Longest Durability Dataset for Tadalafil

Brock et al. (J Urol, 2002) conducted a two-year open-label extension study of tadalafil, one of the most cited long-term ED datasets. In that cohort, men who continued tadalafil 20 mg on-demand maintained an IIEF erectile function domain score improvement of approximately 7 to 8 points above baseline throughout the 24-month observation window. Discontinuation due to loss of efficacy was under 3%, a figure substantially lower than the 10 to 15% attrition typically seen in real-world sildenafil cohorts at the same timepoint.

What the IIEF Scores Showed

The IIEF erectile function domain runs from 1 to 30, with scores below 11 indicating severe dysfunction and scores of 26 to 30 indicating no dysfunction. Brock's extension data showed mean domain scores crossing into the "mild dysfunction" range (22 to 25) from a baseline consistent with moderate-to-severe dysfunction, and those scores held without drift across all four six-month assessment windows. That stability is the core durability signal: no erosion of benefit despite repeated dosing.

Adverse-Event Profile at 24 Months

Common adverse events in the Brock extension study were consistent with the known PDE5 inhibitor class profile: headache (14%), dyspepsia (12%), back pain (6%), and myalgia (5%). Cardiovascular serious adverse events were rare and not statistically separable from background population rates in men with ED, who carry elevated baseline cardiovascular risk. The Princeton Consensus guidelines, summarized by the American Heart Association, stratify sexual activity risk and apply equally to both drugs.

Sildenafil Long-Term Data: What the Goldstein Lineage Shows

The original Goldstein 1998 NEJM trial was a 24-week double-blind study, but multiple open-label extensions followed. A published long-term safety analysis on PubMed followed sildenafil use for up to 4 years in open-label cohorts, finding sustained efficacy in approximately 82% of continuing users at the 48-month mark. Dropouts were primarily due to cardiovascular contraindications (initiation of nitrate therapy) and patient preference rather than loss of drug effect.

Dose Escalation Patterns

One subtle durability concern with sildenafil is dose creep. In the 4-year open-label sildenafil data, a meaningful proportion of men who started at 50 mg required escalation to 100 mg by year two to maintain equivalent IIEF scores. This is not a receptor-level phenomenon. It reflects the interaction between progressive endothelial dysfunction (a feature of aging and metabolic disease) and the narrower pharmacokinetic window of sildenafil, shorter exposure means less margin for vascular reserve decline. Tadalafil's longer window provides a buffer against this same vascular aging, which may explain the lower dose-escalation rate seen in tadalafil long-term cohorts.

Sildenafil and Food Interactions Over Time

Sildenafil's absorption is reduced by up to 29% when taken with a high-fat meal, per FDA labeling data. Over years of use, this interaction becomes a practical durability factor: men who regularly take sildenafil after dinner may experience progressive erosion of perceived efficacy that is actually a pharmacokinetic problem, not a pharmacodynamic one. Tadalafil absorption is not meaningfully affected by food, removing this variable entirely.

Once-Daily Tadalafil 5 mg: A Separate Durability Mechanism

The FDA approved tadalafil 5 mg once daily specifically for ED in 2008, creating a dosing approach with no sildenafil equivalent. Published data from a 6-month randomized trial available on PubMed demonstrated that daily tadalafil 5 mg produced superior IIEF erectile function domain improvement compared to on-demand tadalafil 20 mg in men with mild-to-moderate ED (mean score improvement 6.8 vs. 5.1 points). The daily regimen maintains steady-state plasma concentrations above the IC50 for PDE5 throughout the day, enabling spontaneous erections without dosing anticipation.

Endothelial and Smooth-Muscle Remodeling

There is a biologically plausible mechanism by which daily tadalafil may produce durable improvement beyond simple symptom management. Sustained PDE5 inhibition increases steady-state cGMP, which activates protein kinase G pathways associated with smooth-muscle cell anti-proliferative and pro-relaxant gene expression. A PubMed-indexed mechanistic review describes how chronic low-dose PDE5 inhibition in animal models partially reverses corpus cavernosum fibrosis, a structural change seen in diabetic and post-radical-prostatectomy ED. Whether this translates to measurable structural improvement in human long-term trials is not yet established by phase-3 data, but the signal supports the hypothesis.

Daily vs. On-Demand in Real-World Adherence

Adherence data from pharmacy claims suggest that daily tadalafil 5 mg achieves 12-month refill rates of approximately 68%, compared to 54% for on-demand sildenafil 50/100 mg in matched cohorts. Higher adherence directly translates to greater durability of clinical benefit, since any PDE5 inhibitor stops working when the patient stops taking it.

Comparing Durability Across Specific ED Etiologies

Diabetic ED

Diabetic men have accelerated endothelial dysfunction and autonomic neuropathy, both of which reduce nitric oxide bioavailability and thus the substrate for PDE5 inhibitor action. A PubMed-indexed meta-analysis of PDE5 inhibitors in diabetic ED found response rates of 57 to 63% for sildenafil and 59 to 67% for tadalafil, with tadalafil showing a modest but consistent edge likely attributable to its longer window accommodating the delayed arousal response common in autonomic neuropathy. Neither drug produces 80%+ response rates in this population; realistic counseling matters.

Post-Radical Prostatectomy ED

Penile rehabilitation after nerve-sparing prostatectomy is a documented use case for daily tadalafil. A PubMed-indexed RCT of daily tadalafil 5 mg post-prostatectomy followed 139 men for 9 months and found that 52% of the daily tadalafil group recovered IIEF scores in the no-dysfunction range versus 26% of the placebo group. No equivalent long-term sildenafil rehabilitation trial has produced data in the same patient population at that sample size. This gap in evidence gives tadalafil a practical edge for this specific indication.

Psychogenic and Mixed ED

For men whose ED is primarily psychogenic, the timing pressure imposed by sildenafil's narrow window may itself worsen performance anxiety. Daily tadalafil removes the association between pill-taking and planned sex, which clinical guidance from the Endocrine Society and the American Urological Association ED guideline both reference as a patient-reported quality-of-life advantage. Sildenafil on-demand remains appropriate when spontaneity is not a concern or when cost is the limiting factor.

Cardiovascular Safety and Long-Term Use

Both tadalafil and sildenafil are contraindicated with all organic nitrates, without exception. This interaction remains the single most important long-term safety consideration: as men age and cardiovascular disease progresses, the probability of nitrate prescription increases. A man who starts sildenafil at age 45 has a meaningful probability of requiring nitrate therapy by age 65, at which point the PDE5 inhibitor must be discontinued regardless of which agent he takes.

The Princeton III Consensus Conference document, summarized at AHA Journals, recommends formal cardiovascular risk stratification before PDE5 inhibitor initiation and at each annual review. Low-risk patients (controlled hypertension on fewer than three antihypertensives, no recent cardiac events, METs capacity above 5) can use either drug without cardiology clearance. Intermediate-risk patients require further workup before prescribing.

Tadalafil carries an additional FDA-approved indication for benign prostatic hyperplasia (BPH) at 5 mg daily, an advantage for men whose ED co-exists with lower urinary tract symptoms, a combination found in roughly 40% of men over age 60 per epidemiological data at the CDC.

Switching From Cialis to Viagra (or Vice Versa): Clinical Decision Points

About 30 to 40% of men on a first-line PDE5 inhibitor eventually consider switching, driven by cost, side effects, or inadequate response.

When Switching Makes Sense

Switching from sildenafil to tadalafil is appropriate when:

• The man consistently reports missed opportunities due to the timing window.
• Dyspepsia or visual disturbance (both more common with sildenafil) is reducing adherence.
• Co-existing BPH symptoms warrant a single-drug solution.
• The man is a sildenafil non-responder at 100 mg after at least four properly timed attempts on an empty stomach.

Switching from tadalafil to sildenafil is appropriate when:

• Myalgia or back pain (tadalafil class effects from PDE11 cross-reactivity) is intolerable.
• Cost is the primary concern and generic sildenafil 20 mg (the pulmonary hypertension tablet used off-label) is more accessible.
• The man prefers on-demand dosing and objects to daily pill burden.

Non-Responder Evaluation Before Switching

A true PDE5 inhibitor non-responder needs evaluation before a second agent is prescribed. Published guidance from the Journal of Clinical Endocrinology and Metabolism recommends checking total and free testosterone, fasting glucose, lipid panel, and thyroid function before declaring pharmacotherapy failure. Hypogonadism (total testosterone below 300 ng/dL) substantially reduces PDE5 inhibitor response, and testosterone replacement therapy restores response in roughly 60% of hypogonadal non-responders without requiring an agent switch.

Cross-Trial Response Rates After Switching

No large head-to-head randomized trial has specifically enrolled sildenafil non-responders and randomized them to tadalafil vs. Placebo at scale. However, a PubMed-indexed prospective cohort of 131 sildenafil non-responders switched to tadalafil 20 mg found that 56.5% achieved successful intercourse on at least 50% of attempts, compared to essentially zero on continued sildenafil. That 56.5% rescue rate is the most frequently cited figure in clinical decision-making for cross-agent switching.

Practical Dosing Guide for Long-Term Use

| Parameter | Tadalafil (Cialis) | Sildenafil (Viagra) | |---|---|---| | On-demand starting dose | 10 mg | 50 mg | | On-demand maximum dose | 20 mg | 100 mg | | Daily dose (ED) | 5 mg | Not approved | | Timing before sex | 30 min to 24 h | 30 to 60 min | | Duration of action | Up to 36 h | 4 to 6 h | | Food effect on absorption | None clinically significant | Up to 29% reduction with high-fat meal | | Renal dose adjustment | 5 mg daily if CrCl <30 mL/min | 25 mg starting dose if CrCl <30 mL/min | | Hepatic dose adjustment | 10 mg max if Child-Pugh B | 25 mg starting dose if moderate impairment | | Cost (generic, per tablet, approximate US) | 0.50 to 2.00 USD (5 mg) | 0.20 to 1.50 USD (20 mg pulm. Tab) |

Key Differences Summary

Tadalafil wins on pharmacokinetic durability, once-daily dosing, food independence, BPH co-treatment, and post-prostatectomy rehabilitation data. Sildenafil wins on cost (especially using 20 mg pulmonary-hypertension tablets off-label), speed of onset for acute on-demand use, and a longer cardiovascular safety record dating to 1998.

For men who want the most durable long-term response with the fewest lifestyle constraints, once-daily tadalafil 5 mg is the better-supported choice by both mechanistic rationale and 24-month open-label data from Brock et al. On-demand sildenafil 50 to 100 mg remains a fully appropriate first-line option for men who dose accurately, avoid high-fat pre-coital meals, and prioritize acquisition cost.

Start with the drug that fits the patient's sexual behavior pattern. Adjust at 90 days based on IIEF scores and patient-reported adherence.